SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Graphite Bio, Inc. (GRPH) .
Criteria proven by this page:
- VALUE (75/100, Pass) — analyst target implies upside (+25.8%).
- Analyst consensus target $4.00 (+25.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 42/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GRPH
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio4.80
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.85
Book Value / Share$0.00
Revenue / Share$0.66
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$4.00 (+25.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.09 |
$0.00 |
$-189K |
- |
| 2020 |
$-2.78 |
$0.00 |
$-13.58M |
- |
| 2021 |
$-14.45 |
$0.00 |
$-59.71M |
- |
| 2022 |
$-12.31 |
$0.00 |
$-96.47M |
- |
| 2023 |
$-15.30 |
$0.00 |
$-124.65M |
- |
| 2024 |
$-2.34 |
$0.00 |
$-49.77M |
- |
| 2025 |
$-2.85 |
$19.09M |
$-82.13M |
-430.3% |
